Trending Now
Inflammasome Therapeutics’ Kamuvudine K8 Reduces Geographic Atrophy Lesion Growth by 54% in Phase 2 Study
GenSight Biologics Publishes GS030 PIONEER Optogenetic Therapy Results in the New England Journal of Medicine
Ophthalmology Industry Consolidation Accelerates as MyEyeDr and Glaukos Announce Strategic Deals
Breaking News
Surgical innovation in dry eye disease: Salivary gland transplant
Ağustos 27, 2025
Next-generation IOLs advance complex cataract care
Ağustos 26, 2025
OCT changes with low-level red light therapy for myopia in children
Ağustos 26, 2025
Alcon presenting at APACRS 2025
Ağustos 21, 2025
Breaking News
Popular Now
AAO 2026 Highlights Hospital Ophthalmology Coverage Gaps and Growing Reimbursement Pressures
Access to hospital-based eye care and reimbursement were policy topics at the…
Inflammasome Therapeutics’ Kamuvudine K8 Reduces Geographic Atrophy Lesion Growth by 54% in Phase 2 Study
Phase 2 data for kamuvudine K8, an investigational inflammasome-directed treatment from Inflammasome…
Ophthalmology Industry Consolidation Accelerates as MyEyeDr and Glaukos Announce Strategic Deals
Two transactions announced in September and October 2026 show capital moving through…
GenSight Biologics Publishes GS030 PIONEER Optogenetic Therapy Results in the New England Journal of Medicine
GenSight Biologics and the Quinze-Vingts National Ophthalmology Hospital in Paris announced on…
Collaborate With Us
Join forces with Ophthalmology News to reach a global community of eye care professionals. Whether you want to contribute an article, share research, or explore partnership opportunities, we’d love to hear from you.
Editor Choice
AAO 2026 Highlights Hospital Ophthalmology Coverage Gaps and Growing Reimbursement Pressures
Access to hospital-based eye care and reimbursement were policy topics at the…
Inflammasome Therapeutics’ Kamuvudine K8 Reduces Geographic Atrophy Lesion Growth by 54% in Phase 2 Study
Phase 2 data for kamuvudine K8, an investigational inflammasome-directed treatment from Inflammasome…
GenSight Biologics Publishes GS030 PIONEER Optogenetic Therapy Results in the New England Journal of Medicine
GenSight Biologics and the Quinze-Vingts National Ophthalmology Hospital in Paris announced on…
Ophthalmology Industry Consolidation Accelerates as MyEyeDr and Glaukos Announce Strategic Deals
Two transactions announced in September and October 2026 show capital moving through…
Atsena Therapeutics Reports Preliminary LIGHTHOUSE Results for ATSN-201 Gene Therapy in X-Linked Retinoschisis
Atsena Therapeutics reported preliminary findings on 7 October 2026 from Parts A…
Eyestem Research Presents Eyecyte-RPE Cell Therapy Data in Geographic Atrophy at EURETINA 2026
Eyestem Research presented clinical data for Eyecyte-RPE, an investigational retinal pigment epithelium…
2026 Nobel Prize in Medicine Awarded to Optogenetics Pioneers Deisseroth, Hegemann and Nagel
The 2026 Nobel Prize in Physiology or Medicine has been awarded to…
SpyGlass Pharma Acquires Advanced Vision Science to Advance Drug-Eluting IOL Technology for Glaucoma
SpyGlass Pharma announced on October 1, 2026 that it has acquired Advanced…
Sight Sciences Introduces OMNI Ultra Surgical System at AAO 2026
Sight Sciences announced on October 1, 2026 that it would debut its…
Worth Reading
Meeting expectations with evolving technology
Ağustos 26, 2025
/ Patient Education, Research & Studies, Technology & Innovation, Treatments & Surgery
Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD
Ağustos 26, 2025
/ Industry News, Patient Education, Research & Studies, Treatments & Surgery
Possible protective role of cannabis in preventing postoperative proliferative vitreoretinopathy after retinal detachment repair
Ağustos 26, 2025
/ Patient Education, Research & Studies
Next-generation IOLs advance complex cataract care
Ağustos 26, 2025
/ Patient Education, Research & Studies, Treatments & Surgery
Subscribe Now
Enter your email address below and subscribe to our newsletter